You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The researchers created a test-on-a-chip technology that takes about 35 minutes to produce a result, and may partner with Ford to produce the chips.
The CRISPR-based test uses Mammoth's DETECTR BOOST platform and will be compatible with both nasal swab and saliva samples.
Called CoronaDx, which has a budget of €3 million, aims to facilitate the development of testing systems for use in remote areas with limited infrastructure.
The diagnostics are capable of detecting fewer than two parasites per microliter of blood and would cost an estimated $.61 per test.
The tests are designed to detect viral RNA in individual respiratory specimens, while BayCare's tests can be used with pooled samples.
The CRISPR-COVID assay, which is the first CRISPR-based test for SARS-CoV-2 in China, is faster than PCR-based testing, the researchers said.
The money will be used for research and development, building a clinical laboratory network, and seeking regulatory approval.
The kit, which received EUA from the FDA in May, will be used to test clinical samples from patients at D-HH member hospitals.
The seven technologies feature different methods, including CRISPR and microfluidics, and can be performed in many settings and with a variety of sample types.
Caspr's assay can be transported at room temperature and performed without complex external equipment, making it ideal for low-resource environments.